iwNHL 2017 | CC122: a new IMiD in the treatment of diffuse large B-cell lymphoma
John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses the development of IMiDs at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC, Canada. IMiDs have been shown to have single agent activity, particularly in lymphoma and myeloma. A novel compound being developed for diffuse large B-cell lymphoma is called CC122, shown to be well tolerated, and its administered as orally. It has also been tested in combination with a BTK inhibitor, an MTOR inhibitor, and with anti CD20 antibodies in the relapsed refractory setting. These will hopefully be put through Phase III testing in the near future.
Get great new content delivered to your inboxSign up